Modification of 1-tyrosine-induced keratopathy by adrenal corticosteroids.
D000818:Animals; D001623:Betamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D003318:Corneal Opacity / Q000139:chemically induced* / Q000517:prevention & control; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004044:Dietary Proteins; D004195:Disease Models, Animal; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D007273:Injections, Intramuscular; D007634:Keratitis / Q000139:chemically induced* / Q000517:prevention & control; D008099:Liver / Q000187:drug effects; D009883:Ophthalmic Solutions; D010634:Phenobarbital / Q000627:therapeutic use*; D011241:Prednisone / Q000008:administration & dosage; D051381:Rats; D014443:Tyrosine / Q000097:blood; D014444:Tyrosine Transaminase / Q000096:biosynthesis
D004044:Dietary Proteins; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D014443:Tyrosine; D003907:Dexamethasone; D001623:Betamethasone; D014444:Tyrosine Transaminase; D011241:Prednisone; D010634:Phenobarbital